Home > Gastroenterology > ECCO 2022 > Head-to-Head Comparisons > Vedolizumab outperforms anti-TNF in biologic-naïve ulcerative colitis

Vedolizumab outperforms anti-TNF in biologic-naïve ulcerative colitis

Presented By
Dr Bernd Bokemeyer, University Hospital Schleswig-Holstein, Germany

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ECCO 2022
Trial
VEDO-IBD
After 1 year of maintenance therapy, vedolizumab demonstrated higher clinical response rates than anti-TNF therapy in biologic-naive participants with ulcerative colitis (UC). Also, the treatment persistence was higher for vedolizumab therapy than for anti-TNF therapy, results from the real-world evidence, head-to-head VEDO-IBD study showed. Therefore, vedolizumab may be suggested as first-line biologic therapy in patients with UC. The VEDO-IBD study (NCT03375424) was conducted to compare vedolizumab and anti-TNF therapies head-to-head in biologic-naïve and biologic-experienced patients with UC (n=1,200). The real-world evidence induction study included 314 biologic-naïve participants who were treated according to the physician’s preference and reported comparable response rates among vedolizumab receivers (51.8%) and anti-TNF receivers (54.2%). The 1-yea...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on